All Stories

  1. Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses

    Article • Cancer Biology & Therapy, April 2019, Taylor & Francis

    Professor Francis J Giles

  2. Role of artificial intelligence in the care of patients with nonsmall cell lung cancer

    Article • European Journal of Clinical Investigation, February 2018, Wiley

    Professor Francis J Giles

  3. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis

    Article • Cancer Management and Research, June 2017, Dove Medical Press

    Professor Francis J Giles

  4. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives

    Article • Drug Design Development and Therapy, February 2016, Dove Medical Press

    Professor Francis J Giles, Miss Hannah B Garrett

  5. Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms

    Article • EBioMedicine, January 2016, Elsevier

    Professor Francis J Giles

  6. Blinatumomab for the treatment of acute lymphoblastic leukemia

    Article • Investigational New Drugs, September 2015, Springer Science + Business Media

    Professor Francis J Giles

  7. Targeted therapies in advanced differentiated thyroid cancer

    Article • Cancer Treatment Reviews, September 2015, Elsevier

    Professor Francis J Giles

  8. Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes

    Article • Cell Cycle, June 2015, Taylor & Francis

    Professor Francis J Giles

  9. Novel therapies for myelofibrosis

    Article • Leukemia & Lymphoma, May 2015, Taylor & Francis

    Professor Francis J Giles

  10. Emerging therapeutic targets in bladder cancer

    Article • Cancer Treatment Reviews, February 2015, Elsevier

    Professor Francis J Giles

  11. Mechanisms of Nitric Oxide-Dependent Regulation of Tumor Invasion and Metastasis

    Article • January 2015, Springer Science + Business Media

    Professor Francis J Giles

  12. The Clinical Development of Aurora Kinase Inhibitors in Acute Myeloid Leukemia

    Article • November 2014, Springer Science + Business Media

    Professor Francis J Giles

  13. New strategies for relapsed acute myeloid leukemia

    Article • Current Opinion in Hematology, March 2014, Wolters Kluwer Health

    Professor Francis J Giles

  14. The Role of Inflammation in Leukaemia

    Article • January 2014, Springer Science + Business Media

    Professor Francis J Giles

  15. Erratum to: The Role of Inflammation in Leukaemia

    Article • January 2014, Springer Science + Business Media

    Professor Francis J Giles

  16. The PIM kinases in hematological cancers

    Article • Expert Review of Hematology, February 2012, Taylor & Francis

    Professor Francis J Giles

  17. Editorial [Hot Topic: Targeted Therapies in Oncology (Guest Editor: Monica M. Mita)]

    Article • Current Drug Targets, December 2011, Bentham Science Publishers

    Professor Francis J Giles

  18. The Pim Kinases: New Targets for Drug Development

    Article • Current Drug Targets, December 2011, Bentham Science Publishers

    Professor Francis J Giles

  19. Targeting Aurora Kinases in Cancer Treatment

    Article • Current Drug Targets, December 2011, Bentham Science Publishers

    Professor Francis J Giles

  20. Targeting Trail Towards the Clinic

    Article • Current Drug Targets, December 2011, Bentham Science Publishers

    Professor Francis J Giles

  21. Nilotinib: A Review of its Use in Chronic Myelogenous Leukemia

    Article • Clinical Medicine Insights Therapeutics, November 2010, Libertas Academica, Ltd.

    Professor Francis J Giles

  22. Treating imatinib resistance in the few in CML—A key step towards cure in all

    Article • Leukemia Research, September 2010, Elsevier

    Professor Francis J Giles

  23. Circulating CD33 and its clinical value in acute leukemia

    Article • Experimental Hematology, June 2010, Elsevier

    Professor Francis J Giles

  24. Cdc7 kinase – A new target for drug development

    Article • European Journal of Cancer, January 2010, Elsevier

    Professor Francis J Giles

  25. Overcoming resistance in chronic myelogenous leukemia

    Article • Leukemia & Lymphoma, November 2009, Taylor & Francis

    Professor Francis J Giles

  26. Targeting Sarcomas: Novel Biological Agents and Future Perspectives

    Article • Current Drug Targets, October 2009, Bentham Science Publishers

    Professor Francis J Giles

  27. Laromustine: The return of alkylators to non-myeloablative therapy of AML

    Article • Leukemia Research, August 2009, Elsevier

    Professor Francis J Giles

  28. Reovirus-based therapy for cancer

    Article • Expert Opinion on Biological Therapy, June 2009, Informa Healthcare

    Professor Francis J Giles

  29. Microtubule dynamics as a target in oncology

    Article • Cancer Treatment Reviews, May 2009, Elsevier

    Professor Francis J Giles

  30. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

    Article • Targeted Oncology, April 2009, Springer Science + Business Media

    Professor Francis J Giles

  31. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors

    Article • Targeted Oncology, April 2009, Springer Science + Business Media

    Professor Francis J Giles

  32. Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations

    Article • Cancer, April 2009, Wiley

    Professor Francis J Giles

  33. The toxicities of modern targeted therapies—learning from the price of progress

    Article • Targeted Oncology, April 2009, Springer Science + Business Media

    Professor Francis J Giles

  34. New Directions in the Treatment of Imatinib Failure and/or Resistance

    Article • Seminars in Hematology, April 2009, Elsevier

    Professor Francis J Giles

  35. Targeting the mTOR pathway using deforolimus in cancer therapy

    Article • Future Oncology, April 2009, Future Medicine

    Professor Francis J Giles

  36. Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

    Article • Drug Design Development and Therapy, March 2009, Taylor & Francis

    Professor Francis J Giles

  37. Mammalian Target of Rapamycin as a Target in Hematological Malignancies

    Article • Current Problems in Cancer, July 2008, Elsevier

    Professor Francis J Giles

  38. Current status of therapy for chronic myeloid leukemia: a review of drug development

    Article • Future Oncology, June 2008, Future Medicine

    Professor Francis J Giles

  39. Current Perspectives on the Treatment of Patients with Chronic Myeloid Leukemia: An Individualized Approach to Treatment

    Article • The Cancer Journal, November 2007, Wolters Kluwer Health

    Professor Francis J Giles

  40. Nelarabine activity in acute biphenotypic leukemia

    Article • Leukemia Research, November 2007, Elsevier

    Professor Francis J Giles

  41. A new era for ribonucleoside reductase inhibition

    Article • Leukemia Research, September 2007, Elsevier

    Professor Francis J Giles

  42. Antiangiogenic Therapy for Hematologic Malignancies

    Article • July 2007, Taylor & Francis

    Professor Francis J Giles

  43. Hairy cell leukemia

    Article • Cancer Immunology Immunotherapy, June 2007, Springer Science + Business Media

    Professor Francis J Giles

  44. Recent advances in the diagnosis and therapy of richter’s syndrome

    Article • Cancer Immunology Immunotherapy, June 2007, Springer Science + Business Media

    Professor Francis J Giles

  45. The incidence and impact of thrombocytopenia in myelodysplastic syndromes

    Article • Cancer, May 2007, Wiley

    Professor Francis J Giles

  46. Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia

    Article • Current Hematologic Malignancy Reports, May 2007, Springer Science + Business Media

    Professor Francis J Giles

  47. Ras as a therapeutic target in hematologic malignancies

    Article • Expert Opinion on Emerging Drugs, May 2007, Informa Healthcare

    Professor Francis J Giles

  48. Novel Abl Kinase Inhibitors in Chronic Myeloid Leukemia in Blastic Phase and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

    Article • Clinical Lymphoma & Myeloma, March 2007, Elsevier

    Professor Francis J Giles

  49. Management of Patients with Newly Diagnosed Chronic Myeloid Leukemia: Opportunities and Challenges

    Article • Clinical Lymphoma & Myeloma, March 2007, Elsevier

    Professor Francis J Giles

  50. Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia

    Article • Expert Opinion on Emerging Drugs, March 2007, Informa Healthcare

    Professor Francis J Giles

  51. Acute myeloid leukemia

    Article • January 2007, American Society of Hematology

    Professor Francis J Giles

  52. Approaching the Treatment of AML from a Biological Perspective

    Article • January 2007, Springer Science + Business Media

    Professor Francis J Giles

  53. Treatment of Acute Lymphoblastic Leukaemia

    Article • Drugs, January 2007, Springer Science + Business Media

    Professor Francis J Giles

  54. Bendamustine and cloretazine: Alkylators with sharply contrasting activity in AML

    Article • Leukemia & Lymphoma, January 2007, Taylor & Francis

    Professor Francis J Giles

  55. Current and emerging treatment options in chronic myeloid leukemia

    Article • Cancer, January 2007, Wiley

    Professor Francis J Giles

  56. New Targeted Therapies for Chronic Myelogenous Leukemia: Opportunities to Overcome Imatinib Resistance

    Article • Seminars in Hematology, January 2007, Elsevier

    Professor Francis J Giles

  57. Nilotinib (AMN107) for the Treatment of Chronic Myelogenous Leukemia

    Article • December 2006, Informa Healthcare

    Professor Francis J Giles

  58. Troxacitabine in leukemia

    Article • Hematology, October 2006, Taylor & Francis

    Professor Francis J Giles

  59. The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents

    Article • Targeted Oncology, September 2006, Springer Science + Business Media

    Professor Francis J Giles

  60. Pegylated Interferon Therapy for Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders

    Article • Seminars in Thrombosis and Hemostasis, June 2006, Thieme Publishing Group

    Professor Francis J Giles

  61. New agents in myelodysplastic syndromes

    Article • Current Hematologic Malignancy Reports, March 2006, Springer Science + Business Media

    Professor Francis J Giles

  62. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?

    Article • Hematological Oncology, January 2006, Wiley

    Professor Francis J Giles

  63. Novel approaches in the treatment of systemic mastocytosis

    Article • Cancer, January 2006, Wiley

    Professor Francis J Giles

  64. Editorial [Hot Topic: Mammalian Target of Rapamycin as a Therapeutic Target in Leukemia (Executive Editors: Francis J. Giles / Maher Albitar)]

    Article • Current Molecular Medicine, November 2005, Bentham Science Publishers

    Professor Francis J Giles

  65. Targeting the Kinase Activity of the BCR-ABL Fusion Protein in Patients with Chronic Myeloid Leukemia

    Article • Current Molecular Medicine, November 2005, Bentham Science Publishers

    Professor Francis J Giles

  66. Mammalian Target of Rapamycin as a Therapeutic Target in Leukemia

    Article • Current Molecular Medicine, November 2005, Bentham Science Publishers

    Professor Francis J Giles

  67. Monoclonal Antibodies in the Treatment of Leukemia

    Article • Current Molecular Medicine, November 2005, Bentham Science Publishers

    Professor Francis J Giles

  68. Management of intracranial fungal infections in patients with haematological malignancies

    Article • British Journal of Haematology, November 2005, Wiley

    Professor Francis J Giles

  69. Richterʼs Syndrome

    Article • The Cancer Journal, May 2005, Wolters Kluwer Health

    Professor Francis J Giles

  70. Gemtuzumab ozogamicin: a component of induction therapy in AML?

    Article • Leukemia Research, January 2005, Elsevier

    Professor Francis J Giles

  71. Outcome of patients with acute myelogenous leukemia after second salvage therapy

    Article • Cancer, January 2005, Wiley

    Professor Francis J Giles

  72. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay

    Article • Leukemia Research, December 2004, Elsevier

    Professor Francis J Giles

  73. An update on the management of chronic lymphocytic leukaemia

    Article • Expert Opinion on Pharmacotherapy, July 2004, Informa Healthcare

    Professor Francis J Giles

  74. Interleukin 11 May improve thrombocytopenia associated with Imatinib mesylate therapy in chronic Myelogenous leukemia

    Article • Leukemia Research, June 2004, Elsevier

    Professor Francis J Giles

  75. Investigational strategies in chronic myelogenous leukemia

    Article • Hematology/Oncology Clinics of North America, June 2004, Elsevier

    Professor Francis J Giles

  76. Accelerated and blastic phases of chronic myelogenous leukemia

    Article • Hematology/Oncology Clinics of North America, June 2004, Elsevier

    Professor Francis J Giles

  77. Author reply

    Article • Cancer, January 2004, Wiley

    Professor Francis J Giles

  78. New agents in acute myeloid leukemia and other myeloid disorders

    Article • Cancer, January 2004, Wiley

    Professor Francis J Giles

  79. Nuclear factor-KappaB modulation as a therapeutic approach in hematologic malignancies

    Article • Cancer, January 2004, Wiley

    Professor Francis J Giles

  80. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

    Article • Cancer, January 2004, Wiley

    Professor Francis J Giles

  81. New approaches in the treatment of myelofibrosis

    Article • Cancer, January 2004, Wiley

    Professor Francis J Giles

  82. Activity of interferon-? and isotretinoin in patients with advanced, refractory lymphoid malignancies

    Article • Cancer, January 2004, Wiley

    Professor Francis J Giles

  83. Phase II study of pentostatin in advanced T-cell lymphoid malignancies

    Article • Cancer, January 2004, Wiley

    Professor Francis J Giles

  84. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia

    Article • Cancer, January 2004, Wiley

    Professor Francis J Giles

  85. DNA methylation in haematological malignancies: the role of decitabine

    Article • Expert Opinion on Investigational Drugs, December 2003, Informa Healthcare

    Professor Francis J Giles

  86. Response to Delgado and Fernandez-Jimenez

    Article • British Journal of Haematology, November 2003, Wiley

    Professor Francis J Giles

  87. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

    Article • Cancer, October 2003, Wiley

    Professor Francis J Giles

  88. Vascularity, Angiogenesis and Angiogenic Factors in Leukemias and Myelodysplastic Syndromes

    Article • Leukemia & Lymphoma, January 2003, Taylor & Francis

    Professor Francis J Giles

  89. DNA methylation in haematological malignancies: the role of decitabine

    Article • Expert Opinion on Investigational Drugs, January 2003, Informa Healthcare

    Professor Francis J Giles

  90. New drugs in acute myeloid leukemia

    Article • Current Oncology Reports, October 2002, Springer Science + Business Media

    Professor Francis J Giles

  91. Troxacitabine-based therapy of refractory leukemia

    Article • Expert Review of Anticancer Therapy, June 2002, Taylor & Francis

    Professor Francis J Giles

  92. Novel agents for the therapy of acute leukemia

    Article • Current Opinion in Oncology, January 2002, Wolters Kluwer Health

    Professor Francis J Giles

  93. Essential Thrombocythemia (ET): Moving from Palliation to Cure

    Article • Hematology, January 2002, Taylor & Francis

    Professor Francis J Giles

  94. Oral Mucositis: Time for More Studies

    Article • Hematology, January 2002, Taylor & Francis

    Professor Francis J Giles

  95. Antiangiogenic Therapy in Leukemia

    Article • Acta Haematologica, January 2001, Karger Publishers

    Professor Francis J Giles

  96. A Pilot Study of Recombinant Human Interleukin-4 Therapy of Myelofibrosis

    Article • Journal of Interferon & Cytokine Research, November 1999, Mary Ann Liebert Inc

    Professor Francis J Giles

  97. Monocyte‐Macrophages, Granulocyte‐Macrophage Colony‐Stimulating Factor, and Prolonged Survival Among Patients with Acute Myeloid Leukemia and Stem Cell Transplants

    Article • Clinical Infectious Diseases, June 1998, Oxford University Press (OUP)

    Professor Francis J Giles

  98. Recombinant interferon-? therapy in patients with follicular lymphoma

    Article • Cancer, May 1998, Wiley

    Professor Francis J Giles

  99. Recombinant interferon‐α therapy in patients with follicular lymphoma

    Article • Cancer, May 1998, Wiley

    Professor Francis J Giles

  100. Ring chromosome 6 and i(17q−) in a patient with acute promyelocytic leukemia

    Article • Cancer Genetics and Cytogenetics, September 1988, Elsevier

    Professor Francis J Giles

  101. Diagnosis of Acute Lymphoblastic Leukemia

    Article • Springer Science + Business Media

    Professor Francis J Giles

  102. Faculty of 1000 evaluation for Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

    Article • Faculty of 1000, Ltd.

    Professor Francis J Giles

  103. Faculty of 1000 evaluation for Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.

    Article • Faculty of 1000, Ltd.

    Professor Francis J Giles

  104. Faculty of 1000 evaluation for Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.

    Article • Faculty of 1000, Ltd.

    Professor Francis J Giles